These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31705960)

  • 1. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105838. PubMed ID: 31705960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.
    Morinaka A; Tsutsumi Y; Yamada K; Takayama Y; Sakakibara S; Takata T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Tsujii N; Ida T
    J Antibiot (Tokyo); 2017 Mar; 70(3):246-250. PubMed ID: 27999441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
    Ruiz VH; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa.
    Fratoni AJ; Gethers ML; Nicolau DP; Kuti JL
    Clin Infect Dis; 2024 Jul; 79(1):33-42. PubMed ID: 38306487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.
    Iregui A; Khan Z; Landman D; Quale J
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
    Mushtaq S; Vickers A; Woodford N; Haldimann A; Livermore DM
    J Antimicrob Chemother; 2019 Apr; 74(4):953-960. PubMed ID: 30590470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
    Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases.
    Rotondo CM; Wright GD
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0027224. PubMed ID: 39133022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
    Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.